BiotechTube
Home/Pipeline/Melanoma Immunotherapy

Melanoma Immunotherapy

Melanoma

Pre-clinicalActive

Key Facts

Indication
Melanoma
Phase
Pre-clinical
Status
Active
Company
Vaccizone

About Vaccizone

Vaccizone is a private, pre-clinical stage biotech founded in 2020 and headquartered in London, with significant R&D operations in Istanbul. The company's proprietary ASC technology platform utilizes a modified inflammasome complex (ASC speck) to deliver antigens, offering improved stability, enhanced delivery to antigen-presenting cells, and intrinsic adjuvant properties. Its initial pipeline includes programs for COVID-19, melanoma, and veterinary vaccines, positioning it to address significant unmet needs in vaccine development and immunotherapy.

View full company profile

Therapeutic Areas

Infectious DiseaseOncologyVeterinary Health

Other Melanoma Drugs

DrugCompanyPhase
ABD-3001Advanced BiodesignPhase 1
SUPLEXAAlloplex BiotherapeuticsPhase 1
Cannabics® MLN-33CNBX PharmaceuticalsDiscovery
AV-MEL-1AIVITA BiomedicalPhase 1B
Undisclosed RNA ImmunotherapyEpitopeaPre-clinical
Melanoma Monitoring SolutionOncobitCommercial
Undisclosed Enhanced Antibody ProgramScore PharmaPre-clinical
ASO for MelanomaCarnation TherapeuticsPre-clinical
Personalized DNA Cancer VaccineNeomatrixPre-clinical